NexgenRx's basic earnings per share (Basic EPS) for the
three
months ended in Mar. 2026 was C$0.02.
Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was C$0.03.
NexgenRx's EPS (Diluted) for the
three
months ended in Mar. 2026 was C$0.02.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was C$0.02.
NexgenRx's EPS without NRI for the
three
months ended in Mar. 2026 was C$0.02.
Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 0.03.
During the past 12 months, NexgenRx's average EPS without NRIGrowth Rate was 333.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, NexgenRx's highest 3-Year average EPS without NRI Growth Rate was 52.20% per year. The lowest was -54.80% per year. And the median was 0.00% per year.
NexgenRx (TSXV:NXG) EPS (Basic) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
NexgenRx EPS (Basic) Related Terms
NexgenRx EPS (Basic) Historical Data
* Premium members only.
The historical data trend for NexgenRx's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
NexgenRx's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as
EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.03
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NexgenRx (TSXV:NXG) has a EPS (Basic) of C$0.03 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on NexgenRx and its competitors.
Is NexgenRx's EPS (Basic) too high?
NexgenRx's current EPS (Basic) is C$0.03. Overall, NexgenRx has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NexgenRx's EPS (Basic) compare to VEEV and BTSG?
NexgenRx's EPS (Basic) of C$0.03 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Healthcare Providers & Services company?
A good EPS (Basic) depends on the Healthcare Providers & Services industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on NexgenRx and its competitors. NexgenRx's current EPS (Basic) is C$0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NexgenRx stock overvalued right now?
Based on GuruFocus' analysis, NexgenRx (TSXV:NXG) is currently considered Significantly Overvalued. The stock's GF Value™ is C$0.33, compared to a current price of C$0.45 — trading 34.8% above its estimated fair value. The current EPS (Basic) is C$0.03. NexgenRx's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For NexgenRx (TSXV:NXG), the current EPS (Basic) is C$0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NexgenRx (TSXV:NXG) Overvalued in 2026?
Based on GuruFocus' analysis, NexgenRx stock appears to be overvalued.
The current stock price of C$0.45 is trading 34.8% above its estimated GF Value™ of C$0.33.
GuruFocus considers NexgenRx to be Significantly Overvalued.
Key valuation signals for TSXV:NXG:
EPS (Basic): C$0.03
GF Value™: C$0.33 vs. price of C$0.45 (34.8% above fair value)
No single metric tells the full story. See the TSXV:NXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NexgenRx Inc administers, adjudicates, and pays drug, dental and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers using proprietary computer software and also provides ancillary services. The various solutions offered by the company include: NexSys, a fully integrated rules-based adjudication platform for real-time processing of drug, dental, and extended health benefit claims; NexAdmin, which enables sponsors to take complete control of benefit plan administration; and NexPSPAssist, a service that helps Patient Support Programs (PSP) to optimize their deliverables to their manufacturer clients. The company has only one operating segment - benefits administration services.
57GF Score
Get the complete analysis for TSXV:NXG
EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:NXG has been successfully added to your 
